MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Jan. 5, 2006--ChemoCentryx, Inc., a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine system, today announced the appointment of Susan M. Kanaya to the post of Senior Vice President, Finance and Chief Financial Officer. In this capacity, Ms. Kanaya will oversee financial and accounting operations as well as investor relations. The company also announced the recent appointment of Petrus (Pirow) J. Bekker M.D., Ph.D., to the position of Vice President, Medical and Clinical Affairs and the establishment of ChemoCentryx's clinical development and regulatory affairs department. Both Ms. Kanaya and Dr. Bekker report directly to Thomas Schall, Ph.D., ChemoCentryx's President and Chief Executive Officer.
